AxoGen Stock
AxoGen, Inc.
Company data
- Sector
- Healthcare
- Industry
- Medical - Devices
- Country
- United States
- CEO
- Michael D. Dale
- Employees
- 622
- Market cap
- $2 B
- IPO
- 17/12/1986
AxoGen, Inc., a healthcare company in the medical devices industry based in Alachua, Florida, specializes in creating and distributing medical devices for the surgical repair of injured or severed peripheral nerves. The company offers a comprehensive product portfolio featuring several innovative solutions. This…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
AxoGen stock: price history
1D
-2.8%
1W
-4.2%
1M
-23.8%
6M
-10.1%
YTD
+5.8%
1Y
+106.8%
2Y
+139.4%
5Y
+154.2%
10Y
+295.7%
Next earnings date
Next earnings date
28/10/2026 (in 11 days)
Volatility around earnings
~8% stronger price swings than usual
AxoGen stock scores
- Valuation
Visible after free registration
- Trend
Visible after free registration
- Quality
Visible after free registration
- Dividend
Visible after free registration
- Growth
Visible after free registration
- Insider
Visible after free registration
- Earnings
Visible after free registration
- Revisions
Visible after free registration
- Sentiment
Visible after free registration
- Short Pressure
Visible after free registration
Register for free
Unlock all 11 scores
- 5 credits free on registration
- Access to virtual portfolios and watchlist
- No credit card, no payment details needed
- No subscription, no minimum term
- Our own servers in Germany, no US cloud
Deterministically calculated from financial metrics, not investment advice. Updated nightly, last on 17/10/2026.
Business model & megatrends
Robust business model that benefits noticeably from at least one megatrend.
AxoGen, Inc. develops and commercializes specialized medical products for the surgical repair of damaged or severed peripheral nerves. The portfolio includes biologically active allografts such as Avance Nerve Graft as well as various extracellular matrix-based solutions designed to protect and promote nerve regeneration. Products are supplied to hospitals, surgical centers, and military medical facilities, primarily serving plastic surgeons and orthopedic surgeons. The company is geographically concentrated in the United States, with a product portfolio highly specialized for the treatment of nerve injuries.
- Revenue model
- Hardware sales
- Recurring revenue
- High
- Pricing power
- Moderate
- Moat
- Narrow
- Moat type
- Regulatory
- Capital intensity
- High
- Customer concentration
- Unknown
Ask the agents about AxoGen
Analyst assessment of AxoGen
PRICE TARGET LOW
US$50.00
CONSENSUS
US$53.17
MEDIAN
US$53.00
PRICE TARGET HIGH
US$55.00
0
STRONG BUY
17
BUY
3
HOLD
0
SELL
0
STRONG SELL
20
TOTAL · Buy
As of: 01/10/2026
AxoGen stock metrics
P/E
-51.3
P/B
7.21
EV/EBITDA
-156.42
RETURN ON EQUITY
-0.6%
NET MARGIN
-2.2%
DEBT/EQUITY
0.08
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
Free float & liquidity
FREE FLOAT
83.6%
FLOAT SHARES
49,064,907
AVG. DAILY VOLUME (30D)
1,497,105
Insider transactions (SEC)
TYNDALL JOSEPH A.
Began Marc A
Began Marc A
Wendell Amy McBride
Wendell Amy McBride
Institutional holders
Dividends & Stock splits
Dividends
Stock splits
Comparable stocks
Frequently asked questions about AxoGen stock
What does AxoGen do?
AxoGen, Inc. is a company in the Healthcare sector, Medical - Devices industry, headquartered in United States.
The CEO is Michael D. Dale, the company employs around 622 people.
The IPO was on 17/12/1986; the stock trades on NASDAQ under the ticker AXGN.
What do analysts say about AxoGen stock?
20 analysts rate the stock, the consensus is Buy (as of 01/10/2026).
The average price target is US$53.17, ranging from US$50.00 to US$55.00, with a median of US$53.00.
This is an external assessment, not a statement by Market Jury.
When does AxoGen report next?
The next earnings date is 28/10/2026.
Around past earnings, price swings were roughly 8% stronger than usual.
Does AxoGen pay a dividend?
Yes. The last dividend was US$1.00 per share, ex-date 27/01/2010, paid on 12/02/2010.
The dividend yield is 0.0% (as of 30/06/2026).
Which stocks are comparable to AxoGen?
Comparable stocks include Abbott Laboratories, Stryker, Boston Scientific, Edwards Lifesciences, DexCom, GE HealthCare Technologies, Zimmer Biomet Holdings and Align Technology.
How can I get AxoGen stock analyzed?
Clicking "Analyze stock" lets five strategies assess AxoGen against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.